D. E. Shaw & Co., Inc. - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 121 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$94,807
-57.7%
73,494
-43.7%
0.00%
Q2 2023$224,391
-50.6%
130,460
-56.6%
0.00%
Q1 2023$454,270
-54.1%
300,841
-51.3%
0.00%
-100.0%
Q4 2022$989,399
+39.4%
618,374
+26.3%
0.00%0.0%
Q3 2022$710,000
+56.7%
489,630
+97.8%
0.00%0.0%
Q2 2022$453,000
-0.2%
247,477
+45.6%
0.00%
Q1 2022$454,000
+238.8%
169,951
+546.3%
0.00%
Q3 2021$134,000
-88.8%
26,297
-86.1%
0.00%
-100.0%
Q2 2021$1,199,000
-51.3%
189,444
-40.5%
0.00%
-50.0%
Q1 2021$2,462,000
-39.0%
318,481
-48.3%
0.00%
-50.0%
Q4 2020$4,035,000
+18.4%
615,999
+20.2%
0.00%
+33.3%
Q3 2020$3,408,000
+12.1%
512,488
+40.4%
0.00%
-25.0%
Q2 2020$3,041,000
-24.1%
365,097
-30.1%
0.00%
-33.3%
Q1 2020$4,008,000
-31.1%
522,652
-25.3%
0.01%
-14.3%
Q4 2019$5,818,000
+133.9%
700,101
+107.7%
0.01%
+133.3%
Q3 2019$2,487,000
-33.3%
337,004
+1.4%
0.00%
-40.0%
Q2 2019$3,727,000
-8.7%
332,194
-12.5%
0.01%0.0%
Q1 2019$4,082,000
+102.2%
379,754
+184.1%
0.01%
+66.7%
Q4 2018$2,019,000
-10.8%
133,682
+9.3%
0.00%0.0%
Q3 2018$2,263,000
-8.4%
122,317
+13.2%
0.00%0.0%
Q2 2018$2,470,000
+12.0%
108,053
+39.4%
0.00%0.0%
Q1 2018$2,205,000
+242.9%
77,515
+154.3%
0.00%
+200.0%
Q4 2017$643,000
+183.3%
30,481
+144.2%
0.00%
Q3 2017$227,000
-48.9%
12,483
-41.3%
0.00%
-100.0%
Q4 2015$444,00021,2570.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
BVF INC/IL 5,576,471$36,526,0001.44%
Altium Capital Management LP 273,703$1,793,0000.67%
Jackson Creek Investment Advisors LLC 80,367$526,0000.21%
HARBOURVEST PARTNERS LLC 79,193$519,0000.20%
XTX MARKETS LLC 14,169$93,0000.19%
Perceptive Advisors 2,577,043$16,880,0000.18%
RTW INVESTMENTS, LP 1,527,352$10,004,0000.17%
Exane Asset Management 30,568$200,220,0000.14%
Virtus ETF Advisers LLC 37,343$245,0000.10%
Congress Park Capital LLC 25,807$169,0000.10%
View complete list of CYTOMX THERAPEUTICS INC shareholders